Healthcare Resource Utilization Associated with Intermittent Oral Corticosteroid Prescribing Patterns in Asthma

References

• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention; 2024. Available from: www.ginasthma.org. Accessed June 07, 2024.
   Google Scholar
• Ekstrom M, Nwaru BI, Hasvold P, Wiklund F, Telg G, Janson C. Oral corticosteroid use, morbidity and mortality in asthma: a nationwide prospective cohort study in Sweden. Allergy. 2019;74(11):2181–2190. doi:10.1111/all.13874
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Duh MS, Lafeuille MH, et al. Burden of systemic glucocorticoid-related complications in severe asthma. Curr Med Res Opin. 2017;33(1):57–65. doi:10.1080/03007995.2016.1233101
   PubMed Web of Science ®Google Scholar
• Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703. doi:10.1183/13993003.00703-2018
   PubMed Web of Science ®Google Scholar
• Heatley H, Tran TN, Bourdin A, et al. Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma. Thorax. 2023;78(9):860–867. doi:10.1136/thorax-2022-219642
   PubMedGoogle Scholar
• Chan JSK, Murray RB, Price D. Oral corticosteroids in asthma and beyond: moving forward. Eur Respir J. 2022;60(3):2200776. doi:10.1183/13993003.00776-2022
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Menzies-Gow AN, Price DB, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201(3):276–293. doi:10.1164/rccm.201904-0903SO
   PubMed Web of Science ®Google Scholar
• Wang E, Wechsler ME, Tran TN, et al. Characterization of severe asthma worldwide: data from the International Severe Asthma Registry. Chest. 2020;157(4):790–804. doi:10.1016/j.chest.2019.10.053
   PubMed Web of Science ®Google Scholar
• Dalal AA, Duh MS, Gozalo L, et al. Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma. J Manag Care Spec Pharm. 2016;22(7):833–847. doi:10.18553/jmcp.2016.22.7.833
   PubMedGoogle Scholar
• Voorham J, Xu X, Price DB, et al. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy. 2019;74(2):273–283. doi:10.1111/all.13556
   PubMed Web of Science ®Google Scholar
• Haughney J, Tran TN, Heatley H, et al. Application of an algorithm to analyze patterns of intermittent oral corticosteroid use in asthma. NPJ Prim Care Respir Med. 2023;33(1):9. doi:10.1038/s41533-023-00331-0
   PubMed Web of Science ®Google Scholar
• World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index; 2022. Available from: www.whocc.no/atc_ddd_index/. Accessed November 2, 2022.
   Google Scholar
• National Health Service Digital. Hospital Episode Statistics; 2021. Available from: https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics. Accessed March 4, 2022.
   Google Scholar
• Kousoulis AA, Rafi I, de Lusignan S. The CPRD and the RCGP: building on research success by enhancing benefits for patients and practices. Br J Gen Pract. 2015;65(631):54–55. doi:10.3399/bjgp15X683353
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806–808. doi:10.1136/bmj.39335.541782.AD
   PubMed Web of Science ®Google Scholar
• Curtis LA, Burns A. Unit Costs of Health & Social Care 2020. Kent, UK: Personal Social Services Research Unit; 2020.
   Google Scholar
• NHS England. 2019/20 National Cost Collection Data Publication; 2021. Available from: https://www.england.nhs.uk/publication/2019-20-national-cost-collection-data-publication/. Accessed February 2, 2022.
   Google Scholar
• National Health Service Digital. Prescription Cost Analysis - England, 2018; 2019. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/2018. Accessed February 2, 2022.
   Google Scholar
• Joint Formulary Committee. British National Formulary. 76 ed. London: BMJ Group and Pharmaceutical Press; 2018.
   Google Scholar
• Haymarket Media Group Ltd. Medical Index of Medicinal Substances (MIMS); 2021. Available from: https://www.mims.co.uk/. Accessed March 4, 2022.
   Google Scholar
• Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204. doi:10.2147/JAA.S176026
   PubMed Web of Science ®Google Scholar
• Janson C, Lisspers K, Stallberg B, et al. Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids - a Swedish observational cohort study (PACEHR). Respir Res. 2018;19(1):168. doi:10.1186/s12931-018-0855-3
   PubMedGoogle Scholar
• Zeiger RS, Schatz M, Li Q, Chen W, Khatry DB, Tran TN. Burden of chronic oral corticosteroid use by adults with persistent asthma. J Allergy Clin Immunol Pract. 2017;5(4):1050–1060 e1059. doi:10.1016/j.jaip.2016.12.023
   PubMed Web of Science ®Google Scholar
• Luskin AT, Antonova EN, Broder MS, Chang EY, Omachi TA, Ledford DK. Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis. Clinicoecon Outcomes Res. 2016;8:641–648. doi:10.2147/CEOR.S115025
   PubMed Web of Science ®Google Scholar
• Janson C, Menzies-Gow A, Nan C, et al. SABINA: an overview of short-acting beta2-agonist use in asthma in European countries. Adv Ther. 2020;37(3):1124–1135. doi:10.1007/s12325-020-01233-0
   PubMed Web of Science ®Google Scholar
• Bateman ED, Price DB, Wang HC, et al. Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur Respir J. 2022;59(5): 2101402. doi:10.1183/13993003.01402-2021
   PubMed Web of Science ®Google Scholar
• Quint JK, Arnetorp S, Kocks JWH, et al. Short-acting beta-2-agonist exposure and severe asthma exacerbations: SABINA findings from Europe and North America. J Allergy Clin Immunol Pract. 2022;10(9):2297–2309 e2210. doi:10.1016/j.jaip.2022.02.047
   PubMed Web of Science ®Google Scholar
• Bourdin A, Suehs C, Charriot J. Integrating high dose inhaled corticosteroids into oral corticosteroids stewardship. Eur Respir J. 2020;55(1):1902193. doi:10.1183/13993003.02193-2019
   PubMed Web of Science ®Google Scholar